IMMUNOPRECISE ANTIBODIES LTD.

NASDAQ: HYFT (MindWalk Holdings Corp.)

最近更新时间: 17小时之前

1.76

-0.45 (-20.36%)

  • 1天 -20.36%
  • 5天 -4.86%
  • 1月 -34.81%
  • 6月 310.26%
  • 今年至今天 291.11%
  • 1年 224.72%
  • 5年 -77.22%
前收盘价格 2.21
收盘价格 2.26
成交量 11,253,259
平均成交量 (3个月) 1,906,779
市值 81,231,216
价格/销量 (P/S) 3.56
股市价格/股市净资产 (P/B) 5.11
52周波幅
0.270 (-84%) — 3.25 (84%)
利润日期 15 Sep 2025

AIStockmoo 评分

-0.6
分析师共识 0.0
内部交易活动 NA
价格波动 -4.5
技术平均移动指标 2.5
技术振荡指标 -0.5
平均 -0.63

所有权

姓名 日期 持有股份
Gradient Capital Advisors, Llc 30 Jun 2025 26,808
Tradition Wealth Management, Llc 30 Jun 2025 13,177

该时间范围内无数据。

该时间范围内无数据。

  • 3M
日期 类型 细节
15 Sep 2025 公告 MindWalk Holdings Corp.™ (formerly ImmunoPrecise Antibodies™) Reports Record $7.6 Million Quarterly Revenue, 45% Growth, Margin Expansion, Narrowed Losses, and Strengthened Balance Sheet
10 Sep 2025 公告 MindWalk to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2026 on September 15, 2025
03 Sep 2025 公告 ImmunoPrecise Rebrands as MindWalk, Announces NASDAQ Ticker Change to “HYFT”
02 Sep 2025 公告 ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 27th Annual Global Investment Conference in New York
27 Aug 2025 公告 ImmunoPrecise Advances AI Discovered and Developed Universal Dengue Vaccine Initiative: Moves into Preclinical Antibody Generation
06 Aug 2025 公告 ImmunoPrecise Antibodies Ltd. Divests Netherlands Facilities to AVS Bio to Accelerate Bio-Native AI Innovation
29 Jul 2025 公告 ImmunoPrecise Antibodies (IPA) Reports Full Fiscal Year 2025 Results, Record Fourth Quarter Revenue, and Record Fourth Quarter Adjusted EBITDA
24 Jul 2025 公告 ImmunoPrecise Releases New Findings Showing LENSai™ Quickly Flags Anti-Drug-Antibody Risk—Long Before the Clinic
21 Jul 2025 公告 ImmunoPrecise Appoints Healthcare Data Visionary Jeff Fried to Advisory Board
16 Jul 2025 公告 IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2025 on July 29, 2025
14 Jul 2025 公告 ImmunoPrecise Regains Compliance with Nasdaq Minimum Bid Price Requirement
07 Jul 2025 公告 ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors
03 Jul 2025 公告 ImmunoPrecise Validates LENSai Epitope Mapping Platform Across Broad Range of Unseen Therapeutic Targets Beyond Training Data
24 Jun 2025 公告 ImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using its LENSai™ Platform Powered by Patented HYFT® Technology
显示更多

支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明：以上内容仅供参考，并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票